Imidazo[4,5-c]Pyridine TLR7/8 Agonists for Solid Tumor Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a high unmet clinical need for more potent and balanced Toll-like receptor 7/8 (TLR7/8) agonists to expand treatment options for various cancers, as existing TLR7/8 dual agonists like Resiquimod and BDB-001 show limited efficacy in treating solid tumors.
Innovation Solution
Development of novel imidazo[4,5-c]pyridine compounds that act as dual agonists for TLR7 and TLR8, enhancing immune responses in antigen-presenting cells and other key immune cell types, potentially triggering effective anti-tumor responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TLR7/8 dual agonists like Resiquimod and BDB-001 are used, then immune response activation is achieved, but treatment efficacy for solid tumors is limited
Solution Approach 1:
The patent modifies molecular parameters of TLR agonists by developing novel imidazo[4,5-c]pyridine compounds with specific structural features (R1-R4 substituents, A=O/S/Se, L=bond or C1-6alkylene) to optimize the balance between TLR7 and TLR8 agonist activity, thereby improving treatment efficacy for solid tumors while maintaining immune response activation
Solution Approach 2:
The invention creates composite molecular structures combining imidazo[4,5-c]pyridine core with various aromatic substituents (indazolyl, indolyl, isoquinolinyl, phenyl, pyridyl rings with specific amino alkyl groups) to achieve dual TLR7/8 agonism with enhanced potency and balanced receptor activation profile compared to existing agonists
2Adaptability or versatility
If TLR7 agonists are used selectively, then specific immune response is triggered, but the range of antigen presenting cells activated is limited
Solution Approach 1:
The patent designs TLR agonists with dual bioactivity against both TLR7 and TLR8 receptors, enabling a single compound to activate multiple types of antigen presenting cells (plasmacytoid dendritic cells expressing TLR7, and myeloid dendritic cells, monocytes, macrophages, and neutrophils expressing TLR8), thereby expanding cell type coverage while maintaining manageable molecular complexity
Data Source
AI summary
The present invention relates to compounds of formula (I),wherein R1 to R4, A and L are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.